Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2005 | 12-2004 | 12-2003 | 12-2002 | 12-2001 | |
| Sales | 14,645,300 | 13,857,900 | 12,582,500 | 11,077,500 | 11,542,500 |
| Cost of Goods | 3,474,200 | 3,223,900 | 2,675,100 | 2,176,500 | 2,160,200 |
| Gross Profit | 11,171,100 | 10,634,000 | 9,907,400 | 8,901,000 | 9,382,300 |
| Operating Expenses | 7,522,700 | 7,368,400 | 6,405,699 | 5,657,800 | 5,843,200 |
| Operating Income | 3,648,600 | 3,266,500 | 3,501,801 | 3,243,700 | 3,539,300 |
| Interest Expense | 0 | 0 | 61,000 | 79,700 | 191,700 |
| Other Income | -931,100 | -324,600 | -179,101 | 293,700 | 159,300 |
| Pre-tax Income | 2,717,500 | 2,941,900 | 3,261,700 | 3,457,700 | 3,506,900 |
| Income Tax | 715,900 | 1,131,800 | 700,900 | 749,800 | 726,900 |
| Net Income Continuous | 2,001,600 | 1,810,100 | 2,560,800 | 2,707,900 | 2,780,000 |
| Net Income | $1,979,600 | $1,810,100 | $2,560,800 | $2,707,900 | $2,780,000 |
| EPS Basic Total Ops | 1.82 | 1.67 | 2.38 | 2.51 | 2.58 |
| EPS Basic Continuous Ops | 1.84 | 1.67 | 2.38 | 2.51 | 2.58 |
| EPS Diluted Total Ops | 1.81 | 1.66 | 2.37 | 2.50 | 2.55 |
| EPS Diluted Continuous Ops | 1.83 | 1.66 | 2.37 | 2.50 | 2.55 |
| EBITDA(a) | $4,375,000 | $3,864,000 | $4,050,301 | $3,736,700 | $3,994,200 |